Dr Sandrine Aspeslagh is a medical oncologist and is working at the Department of Medical Oncology at Institute Jules Bordet, Brussels, Belgium. Her main interests are immunotherapy, skin cancers, immune related adverse events and patient communication.
She obtained her PhD in immunology in 2012 at Ghent University through her work with iNKT cells in cancer models in the lab of Prof Dirk Elewaut (rheumatology). The promising results of anti-CTLA-4 immunotherapy made her choose oncology for her further sub-specialisation. Since then she has been working to apply the successes from the immunology research to patients and particularly cancer patients. In 2014, Dr Aspeslagh obtained the Georges Mathé prize for her research in immunotherapy, which gave her the opportunity to join the Drug Development Department (DITEP) at Gustave Roussy Cancer Center in Paris, in the team of Prof Jean-Charles Soria and Dr Aurélien Marabelle. Over the last 2 years, she was the principal investigator of 3 phase I trials and co-investigator for more than 60 Phase I trials (of which at least 20 immunotherapeutical trials). She is organising bi-weekly immune-oncology courses for residents both at DITEP and Institut Jules Bordet, in order to prepare oncologists for the future of immune-oncology.
Dr Aspeslagh is co-author of several publications on immunotherapy and targeted therapy. She is still actively participating to the Immunotoxicity Tumour Board at Gustave Roussy Cancer Centre and is very actively involved in the development of the Immunomanager, an online webtool of the BSMO (Belgian Society of Medical Oncology) on how to deal with immune related adverse events.